Abstract: The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3?-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and ?-1,3-glucan.

Abstract: The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3?-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and ?-1,3-glucan.

Abstract: The present technology relates to an image capture device, a method of image capture, a signal processing device, a method of signal processing, and a program capable of capturing reliably a blinking image capture target. A predetermined image capture timing of an image capture unit is controlled so that image capture is performed N times during an exposure time in which at least a part of a turn-on period in which an image capture target is on overlaps with an exposure time of image capture of at least one time at a timing of dividing a blinking cycle in which the image capture target to be captured by the image capture unit configured to perform image capture at the image capture timing blinks into N equal parts where N represents more than one. The present technology is applicable to, in one example, a camera unit or the like used to capture an image.

Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.

Abstract: It is intended to provide a double-stranded polynucleotide that is resistant to RNase and has RNA interference effect, etc. The present invention provides a double-stranded polynucleotide comprising sense and antisense strands comprising polynucleotides comprising a nucleotide unit of DNAs and 2?-O-methyl RNAs alternately combined.

Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.

Abstract: A compound represented by the general formula (III) which serves as an intermediate of an oligonucleotide analog having stable and excellent antisense or antigene activity or having excellent activity as a detection reagent (probe) for a specific gene or as a primer for the initiation of amplification of a specific gene can be produced at high yields regardless of the type of nucleobase by a method comprising reacting a compound represented by the general formula (II) or a salt thereof with a trimethylsilylated compound obtained from a compound represented by the general formula (IVb), wherein X, Y, Z, A, R, and B are as defined in claim 1.

Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.

Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.

Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.

Abstract: The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3?-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and ?-1,3-glucan.

Abstract: A pair of arcing contacts 3 and 5 facing each other are placed in a tank 1 to perform opening and closing operation, and a puffer cylinder 7 is coaxially provided on the circumference of one arcing contact 5. A puffer chamber 9 is comprised of the puffer cylinder 7, a fixed piston 6, and a hollow rod 8. An insulating nozzle 4 forming a space communicating with the puffer chamber 9 is provided. An exhaust tube 2 for exhausting and cooling hot gas discharged from an arc produced in the insulating nozzle 4 is provided on the circumference of the other arcing contact 3. A structure 11 for temporarily reducing the flow path area is provided on the inner circumferential surface at short of the end portion of the exhaust tube 2.

Abstract: A compound represented by the general formula (III) which serves as an intermediate of an oligonucleotide analog having stable and excellent antisense or antigene activity or having excellent activity as a detection reagent (probe) for a specific gene or as a primer for the initiation of amplification of a specific gene can be produced at high yields regardless of the type of nucleobase by a method comprising reacting a compound represented by the general formula (II) or a salt thereof with a trimethylsilylated compound obtained from a compound represented by the general formula (IVb), wherein X, Y, Z, A, R, and B are as defined in claim 1.

Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.

Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.

Abstract: A pair of arcing contacts 3 and 5 facing each other are placed in a tank 1 to perform opening and closing operation, and a puffer cylinder 7 is coaxially provided on the circumference of one arcing contact 5. A puffer chamber 9 is comprised of the puffer cylinder 7, a fixed piston 6, and a hollow rod 8. An insulating nozzle 4 forming a space communicating with the puffer chamber 9 is provided. An exhaust tube 2 for exhausting and cooling hot gas discharged from an arc produced in the insulating nozzle 4 is provided on the circumference of the other arcing contact 3. A structure 11 for temporarily reducing the flow path area is provided on the inner circumferential surface at short of the end portion of the exhaust tube 2.

Abstract: A compound represented by the general formula (III) which serves as an intermediate of an oligonucleotide analog having stable and excellent antisense or antigene activity or having excellent activity as a detection reagent (probe) for a specific gene or as a primer for the initiation of amplification of a specific gene can be produced at high yields regardless of the type of nucleobase by a method comprising reacting a compound represented by the general formula (II) or a salt thereof with a trimethylsilylated compound obtained from a compound represented by the general formula (IVb), wherein X, Y, Z, A, R, and B are as defined in claim 1.

Abstract: It is intended to provide a polynucleotide that is resistant to RNase and has an RNA interference effect, etc. The present invention provides a single-stranded polynucleotide that is derived from a double-stranded polynucleotide comprising a sense strand polynucleotide corresponding to a target gene, and an antisense strand polynucleotide having a nucleotide sequence complementary to the sense strand polynucleotide, and has a structure in which the 5?-end of the antisense strand and the 3?-end of the sense strand are linked via a phenyl group-containing linker to form a phosphodiester structure at each of these ends.

Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.

Abstract: A display device includes: a front-face member having a transparent plate, a frame having a joint face joined to a rear face of the transparent plate by a joint layer and a holding face provided upright from the joint face, and a hook projected from the holding face of the frame to the outer periphery side of the transparent plate; a display panel which is fit in the frame; a sandwiching member having a pair of clipping faces which come into contact with rear and front faces of the display panel, a side face connecting the pair of sandwiching faces, and an opening which is formed in the side face and to which the hook is inserted; and a rear-face casing covering the entire rear face of the transparent plate.